Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis
Tóm tắt
The objective of this paper is to conduct a systematic review and meta-analysis on the risk of developing elevated antiphospholipid (aPL) antibodies and related thromboembolic and/or pregnancy events following a viral infection.
We searched Medline, EMBASE, Web of Science, PubMed ePubs, and Cochrane Central Register of Controlled Trials through June 2016. Independent observational studies of elevated aPL antibodies in patients with a viral infection compared with controls or patients with lupus were included.
We analyzed 73 publications for 60 studies. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) were most commonly reported. Compared with healthy controls, patients with HIV were more likely to develop elevated anticardiolipin (aCL) antibodies (risk ratio (RR) 10.5, 95% confidence interval (CI) 5.6–19.4), as were those with HCV (RR 6.3, 95% CI 3.9–10.1), hepatitis B virus (HBV) (RR 4.2, 95% CI 1.8–9.5), and Epstein-Barr virus (EBV) (RR 10.9 95% CI 5.4–22.2). The only statistically significant increased risk for anti-β2-glycoprotein I (anti-β2-GPI) antibodies was observed in patients with HCV (RR 4.8 95% CI 1.0–22.3). Compared with patients with lupus, patients with HIV were more likely to develop elevated aCL antibodies (RR 1.8, 95% CI 1.3–2.6), and those with EBV, elevated anti-β2-GPI antibodies (RR 2.2, 95% CI 1.3–3.9). Thromboembolic events were most prevalent in patients with elevated aPL antibodies who had HCV (9.1%, 95% CI 3.0–18.1), and HBV (5.9%, 95% CI 2.0–11.9) infections, and pregnancy events were most prevalent in those with parvovirus B19 (16.3%, 95% CI 0.78–45.7). However, compared to virus-infected patients with negative aPL antibodies, the only statistically significant increased risk was observed in those with HCV and positive aPL.
Viral infection can increase the risk of developing elevated aPL antibodies and associated thromboembolic events. Results are contingent on the reported information.
Từ khóa
Tài liệu tham khảo
Juby AG, 1998, Clin Invest Med, 21, 4
Mchrani T, 2009, Handbook of systemic autoimmune diseases, 13
Wells GA, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 5 August 2017).
The Nordic Cochrane Center TCC, 2014, Copenhagen, Denmark, http://community.cochrane.org/tools/review-production-tools/revman-5/revman-5-download (accessed 5 August 2017).
StataCorp. Stata Statistical Software: Release 11. StataCorp LP; College Station, TX.
Blank A, 1995, J Acquir Immune Defic Syndr Hum Retrovirol, 10, 80
Medina-Rodriguez F, 1993, J Rheumatol, 20, 1880
Johnstone FD, 1992, Obstet Gynecol, 80, 92
Di Prima MA, 1988, Medicina (Firenze), 8, 423
Masala C, 1991, EOS, 11, 109
Matsuda J, 1995, Am J Gastroenterol, 90, 1138
Canoso RT, 1986, Clin Res, 34, A453
Michaelis L, 1907, Berl Klin Wochenschr, 44, 1635
Landsteiner K, 1907, Wien Klin Wochenschr, 20, 1565
Harvey AM, 1974, Lupus erythematosus. 4th ed, 196
Koike T, 1984, Clin Exp Immunol, 56, 193
Hughes GR, 1986, J Rheumatol, 13, 486
Gharavi AE, 1994, J Rheumatol, 21, 94
Barrile A, 1992, Recenti Prog Med, 83, 350
Carreño L, 1994, J Rheumatol, 21, 1344
Chretien P, 2003, Clin Exp Rheumatol, 21, 210
Deril GM, 1995, Clin Chem, 41, S100
González Domínguez J, 1995, Rev Clin Esp (Barc), 195, 8
Agarwal N, 2001, Indian J Med Res, 113, 170
Cacoub P, 1997, J Rheumatol, 24, 2139
Guerrero FJ, 1998, Med Clin (Barc), 110, 319
Nagao Y, 2002, Int J Mol Med, 9, 293
Salazar LA, 2010, Hepat Res Treat, 2010, 971095
Dostál C, 1990, J Rheumatol, 17, 1573
Elías Calvo CJ, 1993, Med Clin (Barc), 100, 797
Ndakotsu MA, 2009, J Microbiol Immunol Infect, 42, 69
Caporali R, 1988, Med Sci Res, 16, 537
Biron C, 1996, Ann Med Interne (Paris), 147, 48
Coll J, 1993, Med Clin (Barc), 100, 357
Dostál C, 1990, Vnitr Lek, 36, 1050
Hunt JE, 1991, FASEB J, 5, A1088